InvestorsHub Logo
Followers 21
Posts 980
Boards Moderated 0
Alias Born 03/20/2019

Re: None

Thursday, 05/26/2022 3:20:32 PM

Thursday, May 26, 2022 3:20:32 PM

Post# of 424560
Karim's comments during the presentation yesterday about other drugs it may make sense to combine Vascepa with.......

Whatever happened to Gilead's Nash trial? Weren't they using Vascepa? Obviously our new Chairman having been on the Board of Gilead would have been privy to those discussions....

I saw that Gilead and Noro Nordisk were collaborating on Nash. Interesting that Noro is a Danish company focused on metabolic diseases and our Chairman has Danish connections as well......I wonder if he knows those folks at Noro. Same country and in bio land.
https://www.fool.com/investing/2019/11/24/does-amarin-have-a-dark-horse-suitor.aspx

https://www.gilead.com/news-and-press/press-room/press-releases/2021/3/gilead-and-novo-nordisk-expand-nash-clinical-collaboration

https://www.reuters.com/article/us-corvidia-m-a-novo-nordisk/novo-nordisk-expands-into-cardiovascular-disease-with-725-million-deal-idUSKBN23I26M

https://www.novonordisk.com/disease-areas.html
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News